Cost-effectiveness of different human papillomavirus vaccines in Singapore
- PMID: 21453537
- PMCID: PMC3082243
- DOI: 10.1186/1471-2458-11-203
Cost-effectiveness of different human papillomavirus vaccines in Singapore
Abstract
Background: Human papillomavirus (HPV) vaccines are widely available and there have been studies exploring their potential clinical impact and cost-effectiveness. However, few studies have compared the cost-effectiveness among the 2 main vaccines available - a bivalent vaccine against HPV 16/18, and a quadrivalent vaccine against 6/11/16/18. We explore the cost-effectiveness of these two HPV vaccines in tropical Singapore.
Methods: We developed a Markov state-transition model to represent the natural history of cervical cancer to predict HPV infection, cancer incidence, mortality, and costs. Cytologic screening and treatment of different outcomes of HPV infection were incorporated. Vaccination was provided to a cohort of 12-year old females in Singapore, followed up until death. Based on available vaccines on the market, the bivalent vaccine had increased effectiveness against a wider range of HPV types, while the quadrivalent vaccine had effectiveness against genital warts. Incremental cost-effectiveness ratios (ICER) compared vaccination to no-vaccination, and between the two vaccines. Sensitivity analyses explored differences in vaccine effectiveness and uptake, and other key input parameters.
Results: For the no vaccination scenario, 229 cervical cancer cases occurred over the cohort's lifetime. The total discounted cost per individual due to HPV infection was SGD$275 with 28.54 discounted life-years. With 100% vaccine coverage, the quadrivalent vaccine reduced cancers by 176, and had an ICER of SGD$12,866 per life-year saved. For the bivalent vaccine, 197 cancers were prevented with an ICER of $12,827 per life-year saved. Comparing the bivalent to the quadrivalent vaccine, the ICER was $12,488 per life-year saved. However, the cost per QALY saved for the quadrivalent vaccine compared to no vaccine was $9,071, while it was $10,392 for the bivalent vaccine, with the quadrivalent vaccine dominating the bivalent vaccine due to the additional QALY effect from reduction in genital warts. The overall outcomes were most sensitive to vaccine cost and coverage.
Conclusion: HPV vaccination is a cost-effective strategy, and should be considered a possible strategy to reduce the impact of HPV infection.
Figures
Similar articles
-
Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.BJOG. 2018 Mar;125(4):478-486. doi: 10.1111/1471-0528.15106. BJOG. 2018. PMID: 29266694
-
Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.BMC Infect Dis. 2013 Feb 7;13:75. doi: 10.1186/1471-2334-13-75. BMC Infect Dis. 2013. PMID: 23390964 Free PMC article.
-
Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.Vaccine. 2013 Aug 20;31(37):3863-71. doi: 10.1016/j.vaccine.2013.06.064. Epub 2013 Jul 3. Vaccine. 2013. PMID: 23830974
-
Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.J Manag Care Pharm. 2010 Apr;16(3):217-30. doi: 10.18553/jmcp.2010.16.3.217. J Manag Care Pharm. 2010. PMID: 20331326 Free PMC article. Review.
-
Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.BioDrugs. 2011 Oct 1;25(5):339-43. doi: 10.2165/11205060-000000000-00000. BioDrugs. 2011. PMID: 21942919 Review.
Cited by
-
Applying a Simple Model of Cost Effectiveness Study of HPV Vaccine for Iran.Iran J Pharm Res. 2015 Spring;14(2):635-49. Iran J Pharm Res. 2015. PMID: 25901173 Free PMC article.
-
Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.PLoS One. 2020 Mar 23;15(3):e0230359. doi: 10.1371/journal.pone.0230359. eCollection 2020. PLoS One. 2020. PMID: 32203527 Free PMC article.
-
Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia.PLoS One. 2013 Nov 18;8(11):e80639. doi: 10.1371/journal.pone.0080639. eCollection 2013. PLoS One. 2013. PMID: 24260441 Free PMC article.
-
Knowledge, attitudes and practices regarding human papillomavirus vaccination among young women attending a tertiary institution in Singapore.Singapore Med J. 2016 Jun;57(6):329-33. doi: 10.11622/smedj.2016108. Singapore Med J. 2016. PMID: 27353611 Free PMC article.
-
Modeling preventative strategies against human papillomavirus-related disease in developed countries.Vaccine. 2012 Nov 20;30 Suppl 5(0 5):F157-67. doi: 10.1016/j.vaccine.2012.06.091. Vaccine. 2012. PMID: 23199959 Free PMC article. Review.
References
-
- World Health Organization (WHO) Projections of mortality and burden of disease. http://www.who.int/healthinfo/global_burden_disease/projections/en/index... [Accessed 29th July 2009]
-
- Health Promotion Board. Singapore. Health Programmes - Cervical Screen Singapore. http://www.hpb.gov.sg/hpb/default.asp?pg_id=1741 [Accessed 27th July 2009]
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical